After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Roivant Sciences Ltd (ROIV) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.0687, or -0.76%, to $8.9913. The Roivant Sciences Ltd has recorded 364,029 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Stocks Info
Roivant Sciences Ltd is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $9.06 and fluctuated between $9.20 as its day high and $8.97 as its day low. The current market capitalization of Roivant Sciences Ltd is $7.17B. A total of 4.12 million shares were traded on the day, compared to an average of 6.18M shares.
In the most recent transaction, Venker Eric sold 153,027 shares of ROIV for 10.11 per share on Oct 05. After the transaction, the Chief Operating Officer now owns 595,397 company shares. In a previous transaction on Oct 03, Venker Eric sold 606,221 shares at 10.25 per share. ROIV shares that Chief Operating Officer owns now total 595,397.
Among the insiders who bought shares, Roivant Sciences Ltd. acquired of 1,526,316 shares on Oct 02 at a per-share price of $38.00. This resulted in the Director holding 79,805,331 shares of ROIV after the transaction. In another insider transaction, Venker Eric sold 440,752 shares at $10.80 per share on Oct 02. Company shares held by the Chief Operating Officer now total 595,397.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ROIV in the last 3 months, the mean price target is $16.44 with high estimates of $23.00 and low estimates of $12.00. In terms of 52-week highs and lows, ROIV has a high of $13.24 and a low of $4.71.
As of this writing, ROIV has an earnings estimate of -$0.31 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.23 per share and a lower estimate of -$0.34. The company reported an EPS of -$0.2 in the last quarter, which was 44.40% higher than expectations of -$0.36.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ROIV’s latest balance sheet shows that the firm has $2.07B in Cash & Short Term Investments as of fiscal 2022. There were $283.89M in debt and $184.37M in liabilities at the time. Its Book Value Per Share was $1.19, while its Total Shareholder’s Equity was $2.04B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Buy with a score of 4.82.
